Phase III, randomized, double-blind, placebo-controlled Advanced-stage, metastatic, or recurrent endometrial cancer of any histologic subtype except for carcinosarcoma Pembrolizuma

15 Mar

Breast Cancer

New Drug: Elacestrant for ER+ Breast Cancer

International, multicenter, randomized, open-label, phase III (EMERALD) ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretre

16 Jul

GastroEsophageal Cancer

New Protocol: Perioperative FLOT with Trastuzumab and Pertuzumab for her2-Positive Gastroesophageal Cancer

Multicenter, randomized phase II/III trial HER 2–positive, >= clinical tumor 2 or clinical nodal–positive resectable EGA Four pre and postoperative cycles of either FLOT alone

20 Sep

Acute myeloid leukemia

New Drug: Enasidenib for IDH2 Mutant AML

International, multicenter, randomized, open-label, phase 3 trial Age ≥60 years, IDH2 gene mutated, de novo or secondary AML Previously 2 or 3 prior AML- directed therapies Enasi

20 May

Biliary Tract Cancer

New Protocol: Pembrolizumab with CISplatin and Gemcitabine in Metastatic Biliary Tract Cancer

Phase III, double-blind, randomized, controlled, multicenter, open-label trial (KEYNOTE-966) Previously untreated, unresectable, locally advanced or metastatic biliary tract cancer

24 Jun

Ovarian Cancer

New Drug: Mirvetuximab Soravtansine in Advanced Ovarian Cancer

A Phase III, Randomized, Open-label trial (MIRASOL) Platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate recep

20 Nov

GastroEsophageal Cancer

New Reference: DOCEtaxel, OXALIplatin, Capecitabine in Locally Advanced Gastric Cancer

Randomized, open-label, phase 3 trial Potentially resectable, locally advanced cT3-4 gastric adenocarcinoma in patients younger than 60 years Neoadjuvant Docetaxel, Oxaliplatin, Ca

20 Nov

Prostate Cancer

New Reference: Enzalutamide in Recurrent Prostate Cancer

Phase 3, randomized, international trial (EMBARK)) Adult patients with prostate cancer who had biochemical recurrence after local therapy and meet the following criteria at screeni

20 Nov

Chronic Lymphocytic Leukemia

New Indication: Pirtobrutinib in CLL

Open-label, multi-center Phase 1/2 study (BRUIN) Relapse/Refractory CLL/SLL who had previously received a BTK inhibitor Pirtobrutinib (n=317)

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries